Search Results - "Marréaud, S"

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS) by Casali, P.G., Le Cesne, A., Velasco, A.P., Kotasek, D., Rutkowski, P., Hohenberger, P., Fumagalli, E., Judson, I.R., Italiano, A., Gelderblom, H., Penel, N., Hartmann, J.T., Duffaud, F., Goldstein, D., Martin-Broto, J., Gronchi, A., Wardelmann, E., Marréaud, S., Zalcberg, J.R., Litière, S., Blay, J.-Y.

“…In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk…”
Get full text

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis by Kollár, A, Jones, R L, Stacchiotti, S, Gelderblom, H, Guida, M, Grignani, G, Steeghs, N, Safwat, A, Katz, D, Duffaud, F, Sleijfer, S, van der Graaf, W T, Touati, N, Litière, S, Marreaud, S, Gronchi, A, Kasper, B

“…Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who…”
Get more information

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M.G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L.H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J.-Y., Reichardt, P., Sufliarsky, J., van der Graaf, W.T.A., Debiec-Rychter, M., Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S., Stacchiotti, S.

“…Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

“…Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and…”
Get full text

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials by Le Cesne, A., Ouali, M., Leahy, M.G., Santoro, A., Hoekstra, H.J., Hohenberger, P., Van Coevorden, F., Rutkowski, P., Van Hoesel, R., Verweij, J., Bonvalot, S., Steward, W.P., Gronchi, A., Hogendoorn, P.C.W., Litiere, S., Marreaud, S., Blay, J.Y., Van Der Graaf, W.T.A.

“…The EORTC-STBSG coordinated two large trials of adjuvant chemotherapy (CT) in localized high-grade soft tissue sarcoma (STS). Both studies failed to…”
Get full text

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072 by Benson, C, Ray-Coquard, I, Sleijfer, S, Litière, S, Blay, J.-Y, Le Cesne, A, Papai, Z, Judson, I, Schöffski, P, Chawla, S, Gil, T, Piperno-Neumann, S, Marréaud, S, Dewji, M.R, van der Graaf, W.T.A

“…Abstract Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery,…”
Get full text

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial by Bui-Nguyen, B, Butrynski, J.E, Penel, N, Blay, J.Y, Isambert, N, Milhem, M, Kerst, J.M, Reyners, A.K.L, Litière, S, Marréaud, S, Collin, F, van der Graaf, W.T.A

“…Abstract Purpose To evaluate whether trabectedin as first-line chemotherapy for advanced/metastatic soft tissue sarcoma prolongs progression-free survival…”
Get full text

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) by Theodore, C., Skoneczna, I., Bodrogi, I., Leahy, M., Kerst, J.M., Collette, L., Ven, K., Marréaud, S., Oliver, R.D.T.

“…The aim of this study is to determine efficacy and feasibility of the combination regimen irinotecan and cisplatin in patients with cisplatin advanced penile…”
Get full text

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy by Touati, N., Schöffski, P., Litière, S., Judson, I., Sleijfer, S., van der Graaf, W.T., Italiano, A., Isambert, N., Gil, T., Blay, J.Y., Stark, D., Brodowicz, T., Marréaud, S., Gronchi, A.

“…Epithelioid sarcoma is a soft tissue sarcoma associated with a high rate of local recurrence after wide resection and high incidence of distant metastasis…”
Get full text

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072 by Kasper, B., Sleijfer, S., Litière, S., Marreaud, S., Verweij, J., Hodge, R.A., Bauer, S., Kerst, J.M., van der Graaf, W.T.A.

“…Pazopanib recently received approval for the treatment of certain soft tissue sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from…”
Get full text

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study by Verschoor, A.J., Litière, S., Marréaud, S., Judson, I., Toulmonde, M., Wardelmann, E., van der Graaf, W.T., Le Cesne, A., Gronchi, A., Gelderblom, H.

“…In patients with advanced soft tissue sarcoma (STS) treated with chemotherapy, WHO performance status, histologic subtype and histologic grade are known…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

Get full text

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974) by Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., Marreaud, S., Collette, L., Lluch, J.R.G., Bokemeyer, C., Schmoll, H.J.

“…To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell…”
Get full text

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours by de Jonge, M.J.A., Dumez, H., Verweij, J., Yarkoni, S., Snyder, D., Lacombe, D., Marréaud, S., Yamaguchi, T., Punt, C.J.A., van Oosterom, A.

“…Halofuginone (tempostatin™) is a synthetic derivative of a quinazolinone alkaloid showing anti-angiogenic, anti-metastatic and anti-proliferative effects in…”
Get full text

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials by Duffaud, F, Sleijfer, S, Litière, S, Ray-Coquard, I, Le Cesne, A, Papai, Z, Judson, I, Schöffski, P, Chawla, S.P, Dewji, R, Marreaud, S, Verweij, J, van der Graaf, W.T

“…Highlights • Pazopanib is an active agent for metastatic non-adipocytic soft tissue sarcomas. • Markers to early identify patients benefiting from treatment…”
Get full text

Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group by Schlemmer, M, Reichardt, P, Verweij, J, Hartmann, J.T, Judson, I, Thyss, A, Hogendoorn, P.C.W, Marreaud, S, Glabbeke, M. Van, Blay, J.Y

“…Abstract Rationale Angiosarcomas of soft tissue represent a heterogenous group of rare sarcomas with specific clinical behaviour and risk factors. Paclitaxel…”
Get full text

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years by Penel, N., Van Glabbeke, M., Marreaud, S., Ouali, M., Blay, J.Y., Hohenberger, P.

“…The prognosis of advanced soft tissue sarcoma remains poor. Many phase II trials investigating new regimens have been published in the last 10 years. Full…”
Get full text

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study by Sleijfer, S, Gorlia, T, Lamers, C, Burger, H, Blay, J-Y, Le Cesne, A, Scurr, M, Collin, F, Pandite, L, Marreaud, S, Hohenberger, P

“…Background: Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline…”
Get full text

PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up by Schmoll, H., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R., Daisne, J., Janssens, J., Brenner, B., Schmidt, P., Reinel, H., Hollerbach, S., Caca, K., Fauth, F., Hannig, C., Zalcberg, J., Tebbutt, N., Mauer, M., Marreaud, S., Lutz, M., Van Cutsem, E.

Get full text

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy by Ray-Coquard, I, Rizzo, E, Blay, J.Y, Casali, P, Judson, I, Hansen, A. Krarup, Lindner, L.H, dei Tos, A.P, Gelderblom, H, Marreaud, S, Litière, S, Rutkowski, P, Hohenberger, P, Gronchi, A, van der Graaf, W.T

“…Abstract Objective UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of…”
Get full text